Novo Nordisk’s once-weekly Sogroya (somapacitan) has proved to be non-inferior to the once-daily growth hormone Norditropin (somatropin) in children’s growth disorders in a Phase III trial. The Danish ...

Superiority was achieved for once-weekly somapacitan versus daily growth hormone in children with NS 2, as well as compared to lower doses of daily growth hormone in children born SGA 1.

Sogroya was more effective at stimulating growth than Norditropin, and the newer drug also outperformed lower doses of the once-daily product in children born with SGA. According to Novo Nordisk ...

Novo Nordisk A/S (NYSE ... in four different but related growth disorder indications, including small for gestational age (SGA), Turner syndrome (TS), Noonan syndrome (NS), and idiopathic short ...

Results from the Phase III REAL8 basket study show that Novo Nordisk’s Sogroya (somapacitan) demonstrated significant efficacy and was well-tolerated in children with growth disorders, including those ...

Novo Nordisk reported positive data ... as well as compared to lower doses of a daily growth hormone in children born small for gestational age. Sogroya also worked at least as well in children ...

(RTTNews) - Novo Nordisk A/S (NVO ... was non-inferior to once-daily growth hormone treatment at Week 52 across three indications - small for gestational age, Noonan syndrome , and idiopathic ...

Sogroya showed 11.0 cm/year growth in SGA children vs 9.4 cm/year with low ... and expert insights—now 60%. Novo Nordisk A/S NVO on Monday presented data from the phase 3 REAL8 basket study ...

Superiority was achieved for once-weekly somapacitan versus daily growth hormone in children with NS 2, as well as compared to lower doses of daily growth hormone in children born SGA 1.